stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Current ratio
Fortrea Holdings Inc.'s current ratio at the end of the quarter to 30 September 2026 was 1.0×, down 0.0× from fiscal 2025 (1.0×). Over the past ten years it has ranged from 1.0× (fiscal 2025) to 1.8× (fiscal 2022) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 5.0× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (1.62%) |
| FY2024 | 1.0× | (37.86%) |
| FY2023 | 1.6× | (9.92%) |
| FY2022 | 1.8× | 31.95% |
| FY2021 | 1.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.0× | 1.10% |
| Jun 2026 | 1.0× | 1.01% |
| Mar 2026 | 0.9× | (3.42%) |
| Dec 2025 | 1.0× | (2.20%) |
| 12 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| IMNM Immunome, Inc. compare | 15.1× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 9.2× |
| REPL Replimune Group, Inc. compare | 7.1× |
| ZYME Zymeworks Inc. compare | 6.3× |
| VIR Vir Biotechnology, Inc. compare | 6.3× |
| SRPT Sarepta Therapeutics, Inc. compare | 3.5× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 3.4× |
| BHVN Biohaven Ltd. compare | 3.1× |
| FTRE Fortrea Holdings Inc. | 1.0× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)